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ABSTRACT
The role of endoplasmic reticulum (ER) stress in cancer has been studied in 
detail, and ER stress is known to increase tumor cell apoptosis, and thus, reduce 
tumor growth. However, in our study, persistent ER stress induced by multiple 
administrations of low-dose thapsigargin (Tg) accelerated tumor growth in mice. 
Tg-mediated ER stress increased the generation of Ly6G+CD11b+ myeloid cells, but 
did not alter anti-tumor effector T cells. 4-Phenylbutyric acid (4-PBA), a chemical 
chaperone widely used as an ER stress reducer, attenuated Tg-induced myeloid-
derived suppressor cell (MDSC) expansion and tumor growth. Tg-mediated ER stress 
enhanced the immunosuppressive capacity of tumor-infiltrating MDSCs by increasing 
expression of ARG1, iNOS, and NOX2, although splenic MDSCs were not affected. 
Consistent with these results, 4-PBA restored the anti-tumor immune response by 
regulating inflammatory cytokines such as TNF-α and CXCL1/KC, and activated tumor-
infiltrating CD8+ T cells that were inhibited by Tg-mediated ER stress. These results 
suggest that significant ER stress in a tumor-bearing host might induce tumor growth 
mediated by enhancement of MDSC-mediated suppression. Therefore, ER stress 
reducers such as 4-PBA could restore anti-tumor immunity by inhibiting suppressive 
MDSCs that are exacerbated by ER stress.
INTRODUCTION
Endoplasmic reticulum (ER) stress induction in 
cancer cells was once a promising strategy for efficiently 
inducing apoptosis of cancer cells, and several ER stress 
inducers, including thapsigargin (Tg), a sarcoplasmic/
endoplasmic Ca2+ ATPase inhibitor, were evaluated as 
anticancer drugs [1]. However, systemic administration 
of Tg induced non-selective apoptosis of host cells, 
including proliferative and quiescent cells [2], indicating 
that Tg might not be a good candidate anticancer drug 
for systemic administration. To overcome this limitation, 
targeted delivery of Tg has been evaluated in several 
murine cancer models [1, 3].
Although direct induction of apoptotic death in 
cancer cells may be critical for therapeutic antitumor 
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effects, the tumor antigen-specific immune response 
against cancer cells has also been shown to efficiently 
inhibit tumor growth and eradicate residual tumor cells. 
In this regard, Tg-induced cell death could beneficially 
induce tumor-specific immunity following phagocytosis 
by dendritic cells [1]. We as well as other researchers have 
provided evidence supporting the combined therapeutic 
strategy of apoptosis induction by anticancer drugs and 
activation of the host immune system to remove residual 
cancer cells [4].
Myeloid-derived suppressor cells (MDSCs) are 
heterogeneous cell populations consisting of immature 
myeloid cells including immature macrophages, 
granulocytes, and dendritic cells. They are found in the 
blood, liver, and spleen, as well as in tumor cells [5, 6]. 
More importantly, it has been suggested that tumor-
associated suppressor cells, including MDSCs, inhibit the 
tumor-specific immune response, and inflammation caused 
by non-selective ER stress-mediated cell death could be 
associated with the induction of MDSC-like cells [7].
Here we investigated the effect of ER stress induced 
by treatment with Tg, an ER stress inducer, on tumor 
growth. Surprisingly, systemic administration of Tg did 
not inhibit tumor growth, but instead, increased tumor 
growth. Although the role of ER stress in cancer has 
been studied in detail, the effects of ER stress on tumor-
associated immune cells, especially MDSCs, have not 
been reported. Thus, we studied the effect of ER stress 
on MDSC generation after Tg administration in vivo. 
Interestingly, persistent and systemic ER stress induced 
by low dose and long-term administration of Tg increased 
MDSC generation in the spleens of tumor-bearing mice. 
More importantly, the immunosuppressive function 
of MDSCs, which is mediated by ARG1, iNOS, and 
NOX2, was also significantly increased by Tg treatment. 
Alleviation of ER stress by the administration of 4-PBA, 
a chemical chaperone used as an ER stress reducer [8], 
effectively restored the level of MDSCs and ameliorated 
their suppressive function in the tumor tissues, but had 
no effect on MDSCs in the spleen. Consistent with these 
results, accelerated tumor growth triggered by Tg was 
inhibited by 4-PBA treatment. These results suggest that 
ER stress in a tumor-bearing host might induce tumor 
growth by reinforcing the suppressive function of MDSCs 
within the tumor microenvironment.
RESULTS
Tg treatment accelerated tumor growth 
in a mouse colon cancer model
Previously, it was reported that induction of ER 
stress increased apoptosis of tumor cells in vitro, and 
therefore, reduced tumor growth in vivo [9]. Tg is a 
well-known ER stress inducer that inhibits sarcoplasmic/
endoplasmic Ca2+-ATPase [1, 10]. Although Tg induces 
apoptosis in both proliferative and quiescent cells, 
it cannot be administered systemically because of 
host toxicity that is related to its non-selectivity [11]. 
However, several reports have shown a direct anticancer 
activity in vivo using a targeted Tg delivery system 
[3, 11]. Thus, we assessed the anticancer activity of Tg 
in a murine colon cancer model. To reduce systemic 
and acute host toxicity, we adopted a low dose and 
long-term Tg treatment regimen. Groups of mice 
were subcutaneously administered 1 × 106 CT26 cells 
expressing HER2/neu (HER2/CT26 cells), and 100 μg/kg 
of Tg was intraperitoneally injected daily starting when 
tumor sizes reached 50-100 mm3. To our surprise, tumor 
growth was significantly increased in mice treated with 
Tg as compared with mice treated with the vehicle control 
(Figure 1A). When isolated tumor masses were analyzed, 
Tg treatment was significantly associated with increased 
tumor weight (Figure 1B). These results suggest that ER 
stress induction by systemic low dose Tg treatment can 
enhance tumor growth in vivo.
Tg evoked ER stress and cell death in  
HER2/CT26 cells in vitro
To verify ER stress in tumor and immune cells in 
the tumor microenvironment, we assessed the ER stress 
response and the subsequent cell death in HER2/CT26 
cells and splenocytes 24 h after Tg treatment. We first 
confirmed the influence of Tg treatment on the ER stress 
response in HER2/CT26 tumor cells by measuring ER 
stress-induced XBP1 mRNA splicing [12]. XBP1 slicing 
was detected when HER2/CT26 cells were treated with 
100 nM Tg (Figure 1C). Tg treatment mediated the ER 
stress response by transcriptional activation of several ER 
stress-related genes, including BiP, TNF-α, Erdj4, CXCL1, 
and ATF4 (Figure 1D, Supplementary Figure 1).
Activation of the PERK-eIF2α pathway is another 
characteristic of the ER stress response. Tg treatment 
increased protein expression of ATF4 and Chop and 
phosphorylation of eIF2α, PERK, and IKBalpha, 
suggesting activation of the PERK-eIF2α pathway 
(Figure 1E). These results clearly show that Tg treatment 
induced ER stress in HER2/CT26 cells. We then evaluated 
whether ER stress induced by Tg treatment influences cell 
death. Tg treatment at concentrations lower than 10 nM 
did not reduce cell viability in HER2/CT26 cells or 
splenocytes (Figures 1F and 1G). However, concentrations 
of Tg greater than 100 nM induced significant cell death in 
HER2/CT26 cells and splenocytes.
These results suggest that Tg treatment at high 
concentrations induces ER stress and cell death. In 
contrast, 10 nM Tg induced the ER stress response 
and increased transcriptional activation of Bip, protein 
expression of ATF4, and phosphorylation of PERK 
without inducing significant cytotoxicity. However, 
considered together with tumor growth observations, these 
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Figure 1: ER stress induced by Tg accelerated tumor growth. (A) BALB/c mice were injected s.c. with 106 HER2/CT26 cells 
per mouse, and 100 µg/kg of Tg was administered i.p. every day before tumor challenge. Tumor growth was monitored (n = 5). (B) tumor 
weight at 4 weeks after HER2/CT26 injection (n = 4). Graphs show mean ± SEM. *p < 0.05, ***p < 0.001 compared with matched control 
group using the Student’s t-test. (C) XBP1 mRNA splicing in Tg-treated HER2/CT26 cells. (D) mRNA levels of BiP from Tg-treated HER2/
CT26 cells as measured by RT-qPCR. (E) immunoblot of Tg-treated HER2/CT26 cells for the PERK-eIF2α branch. (F) HER2/CT26 
cells were cultured with Tg for 24 h and cell viability was analyzed. (G) splenocytes were cultured with Tg for 24 h and cell viability was 
analyzed. ***p < 0.001 using one-way ANOVA with Tukey’s post hoc test.
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effects could not explain the enhanced tumor growth cause 
by Tg treatment.
Tg-mediated ER stress did not decrease the 
generation of antitumor effector T cells
Since Tg treatment significantly increased tumor 
growth in vivo (Figure 1A and 1B), we hypothesized 
that Tg might negatively influence the host immune 
system to reduce tumor protection. Therefore, we 
analyzed CD8+ T cells, which are critical for the 
cytolytic elimination of cancer cells expressing tumor 
antigens. Although there was a significant decrease in 
the percentage of CD8+ T cells in the spleens of mice 
treated with Tg compared with vehicle-treated control 
mice (Figure 2A), the absolute number of splenic CD8+ 
T cells was not changed (Figure 2B). In addition, memory 
CD8+ T cells expressing Ly6C, which are critical for 
successful antitumor activity [13], were not altered 
(Figure 2C). Next, we assessed whether Tg treatment 
Figure 2: Tg-mediated ER stress did not alter anti-tumor effector T cells. (A-B), at 4 weeks after tumor challenge, the percentage 
and absolute number of CD8+ T cells in the spleen was assessed (n = 6). (C) percentages of Ly6C+ CD8+ T cells in the splenocytes of HER2/
CT26 tumor-bearing mice. (D-E) specific lysis of hP63 (TYLPTNASL) peptide-loaded CFSEhigh target cells was estimated by in vivo CTL 
from the spleen and lymph node of HER2/CT26 tumor-bearing mice (n = 6). (F-G) the percentage and absolute number of CD4+ T cells 
in the spleen of HER2/CT26-bearing mice (n = 7). Graphs show mean ±SEM. ns, not significant, **p < 0.01; ***p < 0.001 compared with 
matched control group using the Student's t-test.
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reduces the tumor antigen-specific CTL response by in 
vivo CTL analysis. There was no significant decrease in 
the HER2/neu-specific CTL response after Tg treatment in 
tumor-draining LNs or in the spleen (Figures 2D and 2E). 
We also examined the population of CD4+ T cells. 
Similar to CD8+ T cells, the percentage of CD4+ T cells 
was decreased (Figure 2F), but there was no significant 
decrease in the number of CD4+ cells after Tg treatment 
(Figure 2G). These results indicate that the acceleration 
of tumor growth produced by Tg treatment might not 
be attributed to inhibition of antitumor effector T cells. 
In addition, there appeared to be no significant systemic 
impairment in the tumor antigen-specific cytotoxic activity 
of CD8+ T cells after Tg treatment.
Tg-mediated ER stress increased 
Ly6G+CD11b+ myeloid cells
Because percentages of both CD4+ and CD8+ T cells 
were decreased in mice with larger tumor mass after 
Tg treatment, we hypothesized that immunosuppressive 
myeloid cells might have been expanded. Tg treatment 
significantly increased Ly6G+CD11b+ MDSCs in the 
spleen of HER2/CT26-bearing mice (16.4 ± 2.58%), 
as compared with vehicle control mice (7.0 ± 1.28%, 
Figure 3A and 3B). In the absence of tumor, percentages 
of splenic Ly6G+CD11b+ MDSCs were low regardless 
of Tg treatment. Previously, it was reported that 
Ly6G+CD11b+ MDSCs consisted of more than 2 major 
subsets, including monocytic Ly6Chigh Ly6Gintermediate 
CD11b+ and granulocytic Ly6Cintermediate Ly6Ghigh CD11b+ 
cells. Thus, we investigated changes in the subpopulations 
of CD11b+ MDSCs in mice after Tg treatment. In spite 
of the expansion of Ly6G+CD11b+ MDSCs, the relative 
abundance of each population was not significantly 
changed by Tg treatment (Figures 3C–E). These results 
suggest that Tg treatment might enhance tumor growth via 
modulation of MDSCs.
4-PBA attenuated ER stress-induced 
accelerated tumor growth
Tumor ER stress was recently suggested to be 
linked to the generation of tumor-infiltrating inflammatory 
myeloid cells [14]. Thus, we hypothesized that the 
increased ER stress in the tumor microenvironment could 
lead to induction of MDSCs in vivo, and therefore mediate 
tumor growth enhancement. To test this hypothesis, 
Figure 3: Tg-mediated ER stress increased the generation of Ly6G+CD11b+ myeloid cells. HER2/CT26 tumor-bearing mice 
were treated with 100 µg/kg Tg. At 4 weeks after tumor injection, splenic MDSC populations were analyzed. (A) splenic Ly6G+CD11b+ 
MDSCs. (B) summary graph showing the frequency of Ly6G+CD11b+ cells (n = 6). ns, not significant, **p < 0.01, ***p < 0.001 compared 
with matched control group using one-way ANOVA. (C) MDSC sub-populations, monocyte-derived Ly6ChighLy6Gint and granulocyte-
derived Ly6CintLy6Ghigh among the CD11b+ gated population. (D-E) summary graph of Ly6ChighLy6Gint and Ly6CintLy6Ghigh cells among the 
CD11b+ myeloid cells (n = 4).
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4-PBA was used to attenuate Tg-induced ER stress in 
tumor-bearing mice. 4-PBA is a chemical chaperone 
that can decrease the ER stress response and act as a 
histone deacetylase inhibitor [8]. When the growth of 
HER2/CT26 tumors was monitored, we found that the 
increased tumor growth induced by Tg treatment was 
dramatically inhibited by coadministration of 4-PBA 
(Figure 4A). In another tumor model using TC-1 cells, 
Tg-induced tumor growth was also significantly inhibited 
by coadministration of 4-PBA (Figure 4B). In addition, 
the survival of Tg-treated mice was significantly 
increased by 4-PBA, compared to vehicle treatment group 
(Supplementary Figure 2).
To assess the potential of 4-PBA to reduce MDSC 
generation induced by ER stress, we examined splenic 
MDSCs. Treatment with Tg significantly increased 
Figure 4: (4-PBA) attenuated Tg-induced MDSC expansion and tumor growth. (A) two weeks after HER2/CT26 
tumor inoculation, 100 µg/kg Tg or 10 mg/kg 4-PBA was administered every day. Growth of HER2/CT26 tumors were measured (n = 6). 
*p < 0.05, **p < 0.01 for Tg vs. Tg+4-PBA, #p < 0.05 for vehicle vs. Tg, using one-way ANOVA. (B) two weeks after TC-1 tumor 
inoculation in C57BL/6 mice, 100 µg/kg Tg or 10 mg/kg 4-PBA was administered every day. Growth of TC-1 tumors were measured 
(n = 6). *p < 0.05 using one-way ANOVA. (C) Ly6G+CD11b+ cells in the spleen of HER2/CT26 tumor-bearing mice treated with Tg and/or 
4-PBA. (D and E) percentage and absolute number of Ly6G+CD11b+ MDSCs in the spleen of HER2/CT26 tumor-bearing mice treated with 
Tg and/or 4-PBA (n = 6). ns, not significant, *p < 0.05, **p <0.01 compared with matched control group using one-way ANOVA.
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Ly6G+CD11b+ MDSCs in the spleen, and coadministration 
of 4-PBA significantly reduced the percentage and absolute 
number of Ly6G+CD11b+ MDSCs, as compared with 
those of Tg-treated tumor-bearing mice (Figure 4C-E). 
However, in contrast to the results in splenic MDSCs, 
when tumor-infiltrating MDSCs were examined in tumor-
bearing mice, we found that neither the percentage nor 
the absolute number of Ly6G+ MDSCs was increased 
(Supplementary Figures 3A-C). The subpopulation of 
CD11b+ MDSCs, including Ly6Ghigh  Ly6Cint and Ly6Gint 
Ly6Chigh cells, showed a similar profile, except for an 
increased Ly6Ghigh Ly6Chigh population in the presence of 
ER stress (Supplementary Figure 3D-G). These results 
suggest that 4-PBA mitigates ER stress in the tumor 
microenvironment, leading to reduced tumor growth, 
and inhibits the expansion of splenic, but not tumor-
infiltrating, Ly6G+CD11b+ MDSCs.
ER stress reinforced immunosuppressive 
function of MDSCs within tumor 
microenvironment
MDSCs are known as tumor-associated suppressor 
cells and produce immunosuppression in opposition to 
various types of immune cells, including CD4+ T cell, 
CD8+ T cell, and NK cells [15, 16]. Thus, we compared 
the suppressive function of MDSCs in the spleen and in 
the tumor tissue after Tg and/or 4-PBA treatment. MDSCs 
isolated from the spleen or from tumors were cocultured 
with OT-II peptide-pulsed splenic DCs and CFSE-labeled 
OT-II CD4+ T cells to determine T cell activation status. 
Despite the increased number of MDSCs in the spleen, we 
found no differences in the suppressive function of splenic 
MDSCs among vehicle, Tg, and Tg/4-PBA-treated mice 
(Figure 5A and 5B). In contrast, tumor-infiltrating MDSCs 
showed significantly increased immunosuppressive 
function after Tg treatment, as compared with vehicle 
treatment (Figure 5A and 5C). Treatment with 4-PBA 
significantly inhibited the suppressive function of 
tumor-infiltrating MDSCs under ER stress conditions 
(Figures 5A and 5C).
Several previous studies suggested that the 
immunosuppressive function of MDSCs was partly 
mediated by arginase-1 (ARG1) [17], iNOS [17], and 
reactive oxygen species (ROS) generated by NOX2 
[6, 15, 18]. Therefore, we assessed the transcription 
levels of ARG1, iNOS, and NOX2. Although there 
were no significant changes in the mRNA levels of 
NOX2 and ARG1 in splenic MDSCs among groups, 
the expression levels of NOX2, ARG1, and iNOS were 
significantly increased in tumor-infiltrating MDSCs after 
Tg treatment, as compared with the vehicle control group 
(Figures 5D-I). Surprisingly, Tg-induced up-regulation of 
ARG1, Nox2, and iNOS in tumor-infiltrating MDSCs was 
significantly inhibited by 4-PBA treatment (Figure 5G-I). 
These results suggest that Tg-mediated ER stress enhances 
the immunosuppressive capacity of MDSCs at the local 
tumor site, which was mitigated by 4-PBA treatment.
4-PBA restored anti-tumor immunity via 
dampening suppressive MDSCs exacerbated 
by ER stress
Previously, we reported the conversion of 
immunosuppressive MDSCs into immunogenic Ag-
presenting cells (APCs) using activated invariant NKT 
cells, and that immunogenic APCs converted from 
MDSCs expressed significantly increased levels of 
costimulatory molecules, including CD40 and CD86 [5]. 
When we measured the expression of costimulatory 
molecules in MDSCs, CD40 and CD86 expression on 
splenic MDSCs was not changed by treatment with Tg or 
4-PBA (Supplementary Figure 4).
To identify factors associated with the Tg-mediated 
increased immunosuppressive function of tumor-resident 
MDSCs, we first assessed levels of hypoxia inducible 
factors (HIFs), which have been shown to induce 
tumor angiogenesis and to be increased in the tumor 
microenvironment [19]. Increased levels of HIFα proteins 
activate PI3K-AKT-mTOR-STAT3 signaling [20] and thus 
could enhance the immunosuppressive function of MDSCs 
in tumors. We found that Tg-mediated ER stress induced 
expression of HIF transcription factors (Supplementary 
Figure 5). Tg-mediated increases in HIF-1α and HIF-2α 
in the tumor microenvironment were attenuated by 4-PBA.
In addition, NF-κB-dependent inflammatory 
cytokines such as IL-6, TNF-α, and CXCL1/KC have been 
linked with the enhanced immunosuppressive activity of 
tumor-infiltrating MDSCs [14, 21]. Expression of these 
proinflammatory cytokines was enhanced by Tg-mediated 
ER stress, and this increased expression was attenuated 
by 4-PBA treatment (Figure 6A-C). Finally, we found that 
the abundance and activation status of tumor-infiltrating 
CD8+ T cells were restored by 4-PBA, which might be 
ascribable to attenuated suppressive capacity of MDSCs 
by reduced ER stress (Figure 6D-G). On the contrary, 
tumor-infiltrating CD4+ T cells showed no significant 
differences regardless of treatment. Taken together, these 
results show that 4-PBA restored anti-tumor immunity by 
dampening the ER stress-exacerbated suppressive capacity 
of MDSCs.
DISCUSSION
In the current study, ER stress induced by long-term 
Tg treatment of tumor-bearing mice accelerated tumor 
growth, as compared with that of vehicle-treated mice. 
Relief of ER stress by 4-PBA reduced the tumor growth 
to the level observed in non-treated mice. The tumor 
Oncotarget12338www.impactjournals.com/oncotarget
Figure 5: Tg-mediated ER stress reinforced the immunosuppressive capacity of tumor-infiltrating MDSCs. (A) MDSCs 
were isolated from the spleen or tumors of TC-1 tumor-bearing mice. OT-II peptide-pulsed splenic DCs and CFSE-labeled OT-II CD4+ 
T cells were cocultured with MDSC for 72 h. The percentages of proliferated OT-II CD4+ T cells were determined via analysis of CFSE 
dilution. (B) proliferation of OT-II cells cocultured with spleen-infiltrating MDSCs (n = 3). (C) proliferation of OT-II cells cocultured with 
tumor-infiltrating MDSCs (n = 3). (D-F) mRNA levels of Nox2, Arg1, and iNOS in spleen-infiltrating MDSCs. (G-I) mRNA levels of Nox2, 
Arg1, and iNOS in tumor-infiltrating MDSCs. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001 compared with matched control group 
using one-way ANOVA.
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microenvironment leads to hypoxia, glucose and amino 
acid insufficiency, and ER biosynthesis malfunctioning 
[14, 22]. Thus, there must be an elevation of ER stress 
and the unfolded protein response within tumor cells, and 
tumor-infiltrating cells, including MDSCs, might also be 
under ER stress. However, because 4-PBA alone could 
not induce tumor regression (Supplementary Figure 6), 
we concluded that tumor tissue may possess intrinsic 
mechanisms to cope with ER stress in hypoxic conditions, 
which mimic the effect of 4-PBA.
Figure 6: 4-PBA restored anti-tumor immunity via dampening of suppressive MDSCs exacerbated by ER stress. 
(A-C) mRNA levels of inflammatory cytokines (IL-6, TNF-α, and KC) from spleen- or tumor-filtrating MDSCs. ns, not significant, 
*p < 0.05, ***p < 0.001 using one-way ANOVA. (D) the percentage and absolute number of tumor-infiltrating CD4+ T cells (n = 3). 
(E) the percentage and absolute number of tumor-infiltrating CD8+ T cells (n = 3, one-way ANOVA). (F) surface expression of activation 
markers CD25 and CD69 in tumor-infiltrating CD4+ T cells (n = 3). (G) surface expression of activation markers CD25 and CD69 in tumor-
infiltrating CD8+ T cells (n = 3, one-way ANOVA).
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How systemic ER stress affects MDSC in vivo? 
Enhanced ER stress by Tg treatment increased the number 
and the suppressive function of MDSCs whereas reduced 
ER stress by 4-PBA treatment significantly reduced 
them (Fig 4D-E and supplement Fig 3G). However, Tg 
treatment did not increase the proliferation of CT26 
tumor cells in vitro (Fig 1F). Therefore, we expected that 
ER stress might be able to directly stimulate MDSCs 
expansion and enforce their suppressive activity. On the 
other hand, the larger tumor had more hypoxic condition 
inside the mass than smaller tumor, and consequently can 
influence on the further expansion of MDSCs in vivo. Our 
results showed that ER stress by Tg did not increase the 
proliferation of CT26 cells consistent with several other 
reports (Figure 1F). However, recent studies suggested 
that ER stress can induce GSK-3β activation [23], and 
their activation plays an important role in the proliferation 
of human ovarian and colorectal cancer cells [24, 25]. 
Therefore, we could not rule out the possibility that 
enhanced ER stress could make tumor growth faster, 
which could increase the proliferation and suppressive 
function of MDSCs.
The immunosuppressive function of MDSCs has 
been shown to be dependent on several mechanisms, such 
as arginine and cysteine metabolism and reactive oxygen 
species generation [18, 22]. The expression of iNOS and 
ARG1 in MDSCs has been shown to be especially critical 
for the suppression of T cell function in an antigen-
independent manner [15, 26]. In addition, HIF-1α induced 
under hypoxic conditions was involved in the up-regulation 
of iNOS and ARG1 in MDSCs [22]. HIF-1α induced 
proangiogenic factors such as VEGFR1, PDGF-B, 
and angiopoietins, and HIF-1α expression in MDSCs, 
was associated with immunosuppressive function and 
tumor progression [22, 27]. In contrast, splenic MDSCs, 
which have high levels of NOX2, increased production 
of reactive oxygen species, but failed to suppress 
antigen-independent T cell activation [22]. In addition, 
differences have been reported in the compositions 
of MDSC subsets in the spleen and in tumors [28, 29]. 
Granulocytic MDSCs in the spleen produce high levels 
of ROS via NOX2 [18], whereas up-regulated ARG1 and 
iNOS in tumor-infiltrating MDSCs was reported to be 
critical for their suppressive function [17]. In the current 
study, we found that the level of NOX2 was much higher 
in splenic MDSCs than in tumor-infiltrating MDSCs. 
However, levels of ARG1 and iNOS were significantly 
increased by Tg treatment in tumor-infiltrating MDSCs, 
but not in splenic MDSCs. These results suggest that the 
expression of ARG1 and iNOS in MDSCs is critical for 
their suppressive function, and could be increased by 
Tg-mediated ER stress under hypoxic conditions within 
tumor tissue, because in MDSCs their expression was 
correlated with immunosuppressive capacity against 
CD4+ T cells. Recently, we also showed that Myd88, an 
adaptor molecule critical for the activation of ARG1 and 
NOX2 expression, was critical for the immunosuppressive 
function of MDSCs [6].
The induction of ER stress in cancer cells by 
oxaliplatin or anthracyclines has been shown to induce 
calreticulin (CRT) localization outside the cell membrane, 
which mediates immunogenic apoptosis to stimulate 
tumor-specific CD8+ T cell responses [30]. Tg treatment 
in mouse embryonic fibroblast (MEF) and neuroblastoma 
cells stimulated CRT cell surface exposure through 
ER Ca2+ depletion, and also promoted phagocytosis of 
apoptotic bodies [1]. However, we could not find any 
evidence of increased antitumor immune response caused 
by systemic administration of Tg. Instead, Tg treatment 
accelerated tumor growth as compared to vehicle 
treatment. Thus, ER Ca2+ depletion induced by Tg might 
not be sufficient to induce antigen presentation, even 
though phagocytosis of CRT-exposing apoptotic cancer 
cells was increased. To efficiently induce a tumor-specific 
CD8+ T cell response, an antigen needs to be presented by 
MHC class I molecules after phagocytosis [5]. However, 
this process could be hampered by multiple prerequisite 
steps for successful antigen presentation. Most importantly, 
lysosomal degradation must occur for antigen loading 
into the MHC class I pocket. Degradation of intracellular 
protein or organelles via lysosomal fusion during 
autophagy could increase lysosomal antigen degradation 
for MHC class I presentation [31]. Erp57, an ER-resident 
thiol disulfide oxidoreductase that forms a complex 
with CRT, was recently reported to modulate STAT3 
signaling [32]. Because STAT3 activity is negatively 
regulated by Erp57 and dependent on the formation 
of Erp57-CRT complexes [32], Tg-induced ER stress 
might induce Erp57 malfunction by disassociating it with 
CRT. A further explanation for enhanced Tg-mediated 
tumor growth is its known function as a tumor promoter 
in certain circumstances via the Src-MAP kinase 
pathway [33], and PI-3 kinase-mediated activation of the 
serine/threonine protein kinase protein kinase B (PKB) by 
Tg treatment may enhance survival and proliferation of 
some cell types [34].
4-PBA has been used for the treatment of urea cycle 
disorders in children because of its function as an ammonia 
scavenger [35]. In addition, 4-PBA has also been studied 
as a potential treatment for several cancers, including 
human solid malignant tumors and recurrent malignant 
gliomas [36]. The inhibition of histone deacetylation by 
4-PBA can repress gene expression, including that of genes 
related to tumor suppression, and represents an alternative 
treatment for cystic fibrosis [37]. The histone deacetylation 
inhibition activity of 4-PBA also resulted in decreased 
cancer proliferation [36]. More importantly, the chemical 
chaperone function of 4-PBA, which mimics intracellular 
protein chaperones and promotes protein folding in the 
ER, has been suggested as a means to treat pathological 
conditions related to several abnormal protein localization 
and aggregation disorders, such as Alzheimer’s disease 
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[38], amyotrophic lateral sclerosis [39], and lysosomal 
storage diseases. Indeed, recent studies showed that ER 
stress attenuation by 4-PBA restored glucose homeostasis 
in a mouse model of type 2 diabetes and alleviated colitis 
in mice [40, 41]. Although in this study we focused 
on the function of 4-PBA as a chemical chaperone 
to facilitate the correction of unfolded and misfolded 
proteins in the ER, tumor regression could be partially 
mediated by the inhibitory effect of 4-PBA on histone 
deacetylation [42]. Thus, the effect of butyrate on tumor 
growth after Tg treatment should be assessed, because 
it does not possess chemical chaperone activity, but can 
induce histone hyperacetylation by inhibiting histone 
deacetylation [43].
Several cytokines secreted by MDSCs inhibit 
the function of CTLs [44]. Accordingly, we found that 
Tg-mediated ER stress decreased the number and the 
activation of tumor-infiltrating CD8+ T cells, and 4-PBA 
treatment restored these parameters (Figure 6E and 6G) 
although the number and the activity of CD4+ T cell and 
CD8+ T cells in the spleen and lymph node were not 
affected by ER stress (Figure 2). Therefore, we suggest 
that ER stress reduction by 4-PBA treatment could 
overcome the immunosuppressive environment produced 
by MDSCs, particularly in tumors with excessive ER 
stress induced by Tg treatment, to restore anti-tumor 
immunity nearby tumor mass.
Recent studies showed that ER stress induced by 
Tg in prostate cancer cells up-regulated lipocalin 2 in an 
NF-κB-dependent manner, because ER stress inhibition 
by 4-PBA and NF-κB inhibition by BAY11-7082 inhibited 
lipocalin 2 induction [16]. Thus, combination of 4-PBA 
with NF-κB inhibitors such as MG132 and BAY11-7082 
might reduce ER stress-mediated tumor progression in 
our model. As another possible way to reduce ER stress, 
we and others have examined the consequences of 
activation of autophagy [45, 46]. Autophagy, especially 
macroautophagy, is a lysosomal-dependent degradation 
pathway that removes unnecessary cytosolic proteins and 
organelles, and is activated, at least partly, for the resolution 
of ER stress [47]. Several methods of autophagy activation, 
including treatment with rapamycin, salubrinal, and 
α-mangostin, represent candidates for ER stress reduction 
in cancer models via repression of the immunosuppressive 
function of MDSCs [45, 48, 49]. In addition, lithium 
chloride, a GSK-3β inhibitor, could attenuate Tg-mediated 
enhanced tumor growth, because Tg-induced apoptosis 
was prevented by GSK-3β inhibition [23].
Collectively, in our study, enhanced ER stress in 
tumor-bearing hosts increased tumor growth. Acceleration 
of tumor growth by ER stress was mediated by modulating 
the levels of ARG1 and iNOS in tumor-infiltrating MDSCs, 
which enhanced their immunosuppressive function. 
Therefore, ER stress reducers such as 4-PBA could restore 
anti-tumor immunity by dampening immunosuppressive 
MDSCs that are exacerbated by ER stress.
MATERIALS AND METHODS
Mice
All experiments were approved by the Institutional 
Animal Care and Use Committee of Kangwon 
National University. Wild-type BALB/c and C57BL/6 
mice were purchased from Charles River Laboratories 
(Orient Bio Inc., Sungnam, Korea). OVA-specific 
OT-II (C57BL/6 background) TCR transgenic mice 
were purchased from Jackson Laboratories (Bar Harbor, 
ME). All mice used in the experiments were purchased 
at 6 weeks of age. The mice were kept in the Animal 
Center for Pharmaceutical Research at Kangwon National 
University. To establish tumors, mice were subcutaneously 
(s.c.) injected with 106 tumor cells on the left flank.
Cell line
Human HER2/neu-expressing CT26 cells (hHER2/
CT26) [4, 5, 50] and mouse TC-1 cervical cancer cells 
were used as tumor cells in these studies. To establish 
tumors, 106 HER2/CT26 or TC-1 tumor cells were injected 
s.c. into the left flank of BALB/c or C57BL/6 mice, 
respectively. Tumor growth was measured by calipers 
3 times per week.
Reagents and antibodies
Mice were treated with 100 μg/kg Tg (Sigma-Aldrich, 
St. Louis, MO) and 10 mg/kg sodium 4-phenylbutyrate 
(Calbiochem, San Diego, CA) every day. All antibodies 
used for flow cytometry analysis were purchased from BD 
Biosciences (San Jose, CA).
Isolation of tissue-infiltrating MDSCs
To obtain tissue-infiltrating MDSCs, tumor tissue 
was gently homogenized with a MACS dissociator 
(Miltenyibiotec, Germany) and treated with 0.5 mg/mL 
collagenase type IV (Sigma-Aldrich, St. Louis, MO) 
for 30 min. Cells were harvested by gentle pipetting and 
exposed to a 40–70% percoll gradient to enrich mononuclear 
cells. To isolate MDSCs, cells were treated with an anti-
CD11b+ microbead and isolated by MACS cell separation.
Quantitative real-time PCR
Total RNA was isolated from 106 MDSCs using 
the RNA Extraction Mini Kit (iNtRON, Korea). 
Reverse transcription was performed using the cDNA 
Synthesis Mini Kit (iNtRON), and quantitative real-time 
polymerase chain reaction (PCR) was conducted using 
THUNDERBIRD™ SYBR qPCR Mix (Toyobo, Japan). 
The following primers were used:
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Western blot
Total protein lysates from tumor cells or tissue were 
prepared by sonication in lysis buffer (iNtRON). Equal 
amounts of lysates were boiled at 100°C and resolved 
using 8–12% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes (Millipore, 
Billerica, MA, USA) that were blocked with 5% milk in 
tris-buffered saline and Tween 20 and incubated overnight 
with the primary antibody, and proteins were detected with 
an horseradish peroxidase (HRP)-conjugated antibody 
(Cell Signaling Technology). Membranes were developed 
by the enhanced chemiluminescence (ECL) method using 
femtoLUCENT™ PLUS-HRP (G-Biosciences, St. Louis, 
MO, USA)
In vitro MDSC suppression
OVA-specific TCR transgenic OT-II CD4+ T cells 
(105/well) isolated from the spleens of OT-II 
mice were labeled with 1 μM CFSE, stimulated 
with H-2b-restricted OVA MHC class II epitope 
peptide (ISQAVHAAHAEINEAGR)-pulsed splenic DCs 
(103/well), and cocultured with MDSCs (2 × 105/well) for 
72 h. CFSE dilutions of OT-II CD4+ T cells were analyzed 
using flow cytometry.
In vivo cytotoxicity assay
The in vivo cytotoxicity of CD8+ T cells was 
assessed as described previously [6, 51]. Briefly, syngeneic 
splenocytes and lymph node (LN) cells were divided 
into 2 fractions of equal number that were either loaded 
with 1 μg/mL of cytotoxic T lymphocyte (CTL) epitope 
peptide (human HER2/neu p63 [TYLPTNASL]) or left 
unpulsed. Peptide-pulsed cells were labeled with 10 μM 
CFSE (Invitrogen, Carlsbad, CA) and unpulsed cells were 
labeled with 1 μM CFSE. Equal numbers of CFSEhigh and 
CFSElow cells were mixed and injected intravenously into 
mice. After 24 h, the splenocytes from treated mice were 
analyzed to assess antigenic peptide-specific target lysis. 
The specific lysis was calculated as follows:
r (ratio) = (%CFSElow/%CFSEhigh)
% lysis = (1 - [runprimed /rprimed]) × 100
iNOS
forward 5′-AGGAAGTGGGCCGAAGGAT-3′
reverse 5′-GAAACTATGGAGCACAGCCACAT-3′
ARG1
forward 5′-AACACGGCAGTGGCTTTAACCT-3′
reverse 5′-GTGATGCCCCAGATGGTTTTC-3′
Nox2
forward 5′-GACCCAGATGCAGGAAAGGAA-3′
reverse 5′-TCATGGTGCACAGCAAAGTGAT-3′
BiP
forward 5′-ACTTGGGGACCACCTATTCCT-3′
reverse 5′-ATCGCCAATCAGACGCTCC-3′
ATF4
forward 5′-ATGGCCGGCTATGGATGAT-3′
reverse 5′-CGAAGTCAAACTCTTTCAGATCCATT-3′
Chop
forward 5′-CTGGAAGCCTGGTATGAGGAT-3′
reverse 5′-CAGGGTCAAGAGTAGTGAAGGT-3′
Erdj4
forward 5′-TCAGAGAGATTGCAGAAGCG-3′
reverse 5′-GACTCCCATTGCCTCTTTGT-3′
IL-6
forward 5′- CTGGAGTCACAGAAGGAGTGG-3′
reverse 5′- GGTTTGCCGAGTAGATCTCAA-3′
CXCL1/KC
forward 5′- TGAGCTGCGCTGTCAGTGCC-3′
reverse 5′- GCGTTCACCAGACGGTGCCA-3′
TNF-α
forward 5′- TGGGAGTAGACAAGGTACAACCC-3′
reverse 5′- CATCTTCTCAAAATTCGAGTGACAA-3′
β-actin
forward 5′-CCTAGGCACCAGGGTGTGAT-3′
reverse 5′-TCTCCATGTCGTCCCAGTTG-3′
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Determination of cell viability
Cell viability was determined using the Dojindo 
Cell Counting Kit-8 (Dojindo, Gaithersburg, MD, USA) 
according to the manufacturer’s instructions. Splenocytes 
and tumor cells were seeded in 96-well plates and allowed 
to adhere overnight. The cells were treated with Tg at 
37°C for 24 h. The absorbance at 450 nm was measured 
with a SPECTRA MAX 340 instrument (Molecular 
Devices, US).
Statistical analysis
Student’s t-test was used to compare differences 
between the 2 groups. To compare multiple groups, we 
performed one-way ANOVA followed by Tukey’s post hoc 
test. Values of p < 0.05 were considered to be significant.
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